Eli Lilly and Company moved -0.0% this afternoon session, trading between a high of $595.0899 and a low of $581.7501 per share. Yesterday the stock finished at $588.54 per share, compared to an average analyst target price of $557.88.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 0.7%. Eli Lilly and Company has trailing twelve months earnings per share (EPS) of 5.53, which at today's prices amounts to a price to earnings (P/E) ratio of 106.4.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of 3.94. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
---|---|---|---|---|
2023 | 29,515,500 | 6,561,300 | 78 | 1.3 |
2022 | 28,541,400 | 6,629,800 | 77 | 4.05 |
2021 | 28,318,400 | 7,312,800 | 74 | -5.13 |
2020 | 24,539,800 | 5,483,300 | 78 | -1.27 |
2019 | 22,319,500 | 4,721,200 | 79 | 1.28 |
2018 | 21,493,300 | 4,681,700 | 78 |
At 77.3%, Eli Lilly and Company's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.